Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1

Antibody-based immune checkpoint blockade (ICB)-based therapeutics have become effective clinical applications for cancers. Applications of monoclonal antibodies (mAbs) to de-activate the PD-1-PD-L1 pathway could effectively reverse the phenotype of depleted activated thymocytes (T cells) to recover...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Mengzhen, Liu, Man, Liu, Guodi, Ma, Jiawen, Zhang, Lixin, Wang, Shenlin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10399482/
https://www.ncbi.nlm.nih.gov/pubmed/37530414
http://dx.doi.org/10.1080/19420862.2023.2236740

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10399482/
https://www.ncbi.nlm.nih.gov/pubmed/37530414
http://dx.doi.org/10.1080/19420862.2023.2236740

Ejemplares similares